この記事は最初に2025年10月2日に英語で公開されました スプルーソン＆ファーガソンによる、過去1年間におけるオーストラリアの医薬品特許法に関する主要な動向の評論へようこそ。
この記事は最初に2025年10月2日に英語で公開されました スプルーソン＆ファーガソンによる、過去1年間におけるオーストラリアの医薬品特許法に関する主要な動向の評論へようこそ。
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past year.The year has seen a series of landmark decisions from...
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past...
Over recent years, Australian courts have heard a growing number of challenges to pharmaceutical patent term extensions (PTEs). The decisions in these cases signal an increasingly contentious landscape for...
Over recent years, Australian courts have heard a growing number of challenges to pharmaceutical patent term extensions (PTEs). The...
The recent Federal Court ruling in Novartis AG v Pharmacor Pty Limited (No 3) FCA 1307 highlights an increasing trend of challenging patents during the extended term granted based on...
The recent Federal Court ruling in Novartis AG v Pharmacor Pty Limited (No 3) FCA 1307 highlights an increasing trend...
The Indian patent office strikes again – patent application refused as chemical variant of known compound is not considered an invention according to Section 3(d)
In a recent decision, the...
The Indian patent office strikes again – patent application refused as chemical variant of known compound is not considered...